| pubmed-article:16247432 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16247432 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:16247432 | lifeskim:mentions | umls-concept:C0085669 | lld:lifeskim |
| pubmed-article:16247432 | lifeskim:mentions | umls-concept:C0016884 | lld:lifeskim |
| pubmed-article:16247432 | lifeskim:mentions | umls-concept:C0243019 | lld:lifeskim |
| pubmed-article:16247432 | pubmed:issue | 12 | lld:pubmed |
| pubmed-article:16247432 | pubmed:dateCreated | 2005-12-1 | lld:pubmed |
| pubmed-article:16247432 | pubmed:abstractText | Targeted radiotherapy of the bone marrow using radiolabeled monoclonal antibodies is a therapeutic approach of considerable potential for the treatment of acute leukemia in addition to or as a substitute for total body irradiation. The data currently available, of about 300 patients, suggest that radioimmunotherapy (RIT) with beta-emitters in acute leukemia is feasible and safe using a variety of antibodies (anti-CD33, anti-CD45, anti-CD66) and radionuclides (131I, 90Y, 188Re). It appears to reduce the risk of relapse in high-risk acute myelogenous leukemia (AML) patients transplanted early in the course of their disease (<15% blasts) to 20-30%. Furthermore, it has shown the potential to safely intensify reduced-intensity conditioning regimens (nonrelapse mortality of 25% compared to relapse rate of 55% within 2 years). Significant improvements in the results of refractory patients will probably depend on the successful further development of RIT with alpha-emitters or the use of a cocktail of antibodies labeled with alpha- and beta-emitters, in a first dose escalation study of 213Bi-labeled anti-CD33 in refractory AML (partial) remission could be achieved in 5/18 patients. Randomized trials to evaluate the therapeutic efficacy of RIT in the context of stem cell transplantation have been initiated and the results are keenly anticipated. | lld:pubmed |
| pubmed-article:16247432 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16247432 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16247432 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16247432 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16247432 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16247432 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16247432 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16247432 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16247432 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16247432 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16247432 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16247432 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16247432 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16247432 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16247432 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16247432 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:16247432 | pubmed:issn | 0268-3369 | lld:pubmed |
| pubmed-article:16247432 | pubmed:author | pubmed-author:BunjesDD | lld:pubmed |
| pubmed-article:16247432 | pubmed:author | pubmed-author:ScheinbergD... | lld:pubmed |
| pubmed-article:16247432 | pubmed:author | pubmed-author:KotzerkeJJ | lld:pubmed |
| pubmed-article:16247432 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16247432 | pubmed:volume | 36 | lld:pubmed |
| pubmed-article:16247432 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16247432 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16247432 | pubmed:pagination | 1021-6 | lld:pubmed |
| pubmed-article:16247432 | pubmed:dateRevised | 2009-11-19 | lld:pubmed |
| pubmed-article:16247432 | pubmed:meshHeading | pubmed-meshheading:16247432... | lld:pubmed |
| pubmed-article:16247432 | pubmed:meshHeading | pubmed-meshheading:16247432... | lld:pubmed |
| pubmed-article:16247432 | pubmed:meshHeading | pubmed-meshheading:16247432... | lld:pubmed |
| pubmed-article:16247432 | pubmed:meshHeading | pubmed-meshheading:16247432... | lld:pubmed |
| pubmed-article:16247432 | pubmed:meshHeading | pubmed-meshheading:16247432... | lld:pubmed |
| pubmed-article:16247432 | pubmed:meshHeading | pubmed-meshheading:16247432... | lld:pubmed |
| pubmed-article:16247432 | pubmed:meshHeading | pubmed-meshheading:16247432... | lld:pubmed |
| pubmed-article:16247432 | pubmed:meshHeading | pubmed-meshheading:16247432... | lld:pubmed |
| pubmed-article:16247432 | pubmed:meshHeading | pubmed-meshheading:16247432... | lld:pubmed |
| pubmed-article:16247432 | pubmed:meshHeading | pubmed-meshheading:16247432... | lld:pubmed |
| pubmed-article:16247432 | pubmed:meshHeading | pubmed-meshheading:16247432... | lld:pubmed |
| pubmed-article:16247432 | pubmed:meshHeading | pubmed-meshheading:16247432... | lld:pubmed |
| pubmed-article:16247432 | pubmed:meshHeading | pubmed-meshheading:16247432... | lld:pubmed |
| pubmed-article:16247432 | pubmed:meshHeading | pubmed-meshheading:16247432... | lld:pubmed |
| pubmed-article:16247432 | pubmed:meshHeading | pubmed-meshheading:16247432... | lld:pubmed |
| pubmed-article:16247432 | pubmed:meshHeading | pubmed-meshheading:16247432... | lld:pubmed |
| pubmed-article:16247432 | pubmed:meshHeading | pubmed-meshheading:16247432... | lld:pubmed |
| pubmed-article:16247432 | pubmed:meshHeading | pubmed-meshheading:16247432... | lld:pubmed |
| pubmed-article:16247432 | pubmed:meshHeading | pubmed-meshheading:16247432... | lld:pubmed |
| pubmed-article:16247432 | pubmed:year | 2005 | lld:pubmed |
| pubmed-article:16247432 | pubmed:articleTitle | Radioimmunoconjugates in acute leukemia treatment: the future is radiant. | lld:pubmed |
| pubmed-article:16247432 | pubmed:affiliation | Klinik und Poliklinik für Nuklearmedizin, Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany. joerg.kotzerke@mailbox.tu-dresden.de | lld:pubmed |
| pubmed-article:16247432 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16247432 | pubmed:publicationType | Review | lld:pubmed |
| pubmed-article:16247432 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16247432 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16247432 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16247432 | lld:pubmed |
